Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harvard Apparatus Regenerative Technology, Inc.BSTG · Entity 7501 | Director | June 25, 2020 | June 29, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harvard Apparatus Regenerative Technology, Inc.
Report date June 25, 2020 · Filed June 29, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.52 · Expires 2030-06-25 | Direct | 11,938 |
Reported balance
After 2020-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-25 · Grant · Acquired 11,938 · Balance 11,938 F1: This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 25, 2020, December 25, 2020, March 25, 2021, and June 25, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.52 · Expires 2030-06-25 | Direct | 21,517 |
Reported balance
After 2020-06-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-25 · Grant · Acquired 9,579 · Balance 21,517 F2: This Stock Option was granted in lieu of 2020 cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2020, September 30, 2020 and December 31, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 25, 2020, December 25, 2020, March 25, 2021, and June 25, 2021.
F2: This Stock Option was granted in lieu of 2020 cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2020, September 30, 2020 and December 31, 2020.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
JUNIPER PHARMACEUTICALS INC
Report date August 14, 2018 · Filed August 15, 2018
Section 16 reporting ended · disclosed 2018-08-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-08-14 transaction · row 1
1 source rowRow 1 · 2018-08-14 · Disposition to issuer · Disposed 30,413 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the "Issuer") dated as of July 2, 2018. At the effective time of the merger (the "Effective Time") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the "Offer Price"). F2: Includes 27,150 restricted stock units that did not vest prior to the Effective Time of the merger. Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unvested 27,150 restricted stock units was cancelled in exchange for the Offer Price. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.90 · Expires 2025-02-09 | Direct | 0 |
Reported balance
After 2018-08-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-08-14 · Disposition to issuer · Disposed 40,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options. |
| Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 · Expires 2024-01-03 | Direct | 0 |
Reported balance
After 2018-08-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-08-14 · Disposition to issuer · Disposed 170,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the "Issuer") dated as of July 2, 2018. At the effective time of the merger (the "Effective Time") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the "Offer Price").
F2: Includes 27,150 restricted stock units that did not vest prior to the Effective Time of the merger. Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unvested 27,150 restricted stock units was cancelled in exchange for the Offer Price.
F3: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2020 Filed Jun 29, 2020 19:53 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantStock Option (right to buy) · Derivative | 9,579 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001104659-20-078207 · tm2023734d5_4.xml · derivative · entry 2 Young Jeffrey E · CIK 0001367556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,517 Underlying: Common Stock, par value $0.01 per share · 9,579 shares Expires 2030-06-25 F2 · derivative.exercise_date: This Stock Option was granted in lieu of 2020 cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2020, September 30, 2020 and December 31, 2020. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 19:53 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantStock Option (right to buy) · Derivative | 11,938 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001104659-20-078207 · tm2023734d5_4.xml · derivative · entry 1 Young Jeffrey E · CIK 0001367556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,938 Underlying: Common Stock, par value $0.01 per share · 11,938 shares Expires 2030-06-25 F1 · derivative.exercise_date: This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 25, 2020, December 25, 2020, March 25, 2021, and June 25, 2021. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 16:35 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | OtherWarrant (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001144204-19-046964 · tv530558_4.xml · derivative · entry 3 Young Jeffrey E · CIK 0001367556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-12-27 Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 16:35 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | OtherWarrant (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001144204-19-046964 · tv530558_4.xml · derivative · entry 2 Young Jeffrey E · CIK 0001367556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2022-12-27 F1 · kind: These warrants were transferred to the Reporting Person by DST Capital LLC on the condition that the Reporting Person immediately exercise the Warrants for cash. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 16:35 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | OtherCommon Stock | 25,000 | $2.00 | $50,000.00 |
DisclosureSEC source: 0001144204-19-046964 · tv530558_4.xml · nonDerivative · entry 1 Young Jeffrey E · CIK 0001367556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:32 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantStock Option (right to buy) · Derivative | 8,411 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001144204-19-029896 · tv523169_form4.xml · derivative · entry 2 Young Jeffrey E · CIK 0001367556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,775 Underlying: Common Stock, par value $0.01 per share · 8,411 shares Expires 2029-06-03 F2 · derivative.exercise_date: This Stock Option was granted in lieu of 2019 cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2019, September 30, 2019, and December 31, 2019. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:32 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantStock Option (right to buy) · Derivative | 10,364 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001144204-19-029896 · tv523169_form4.xml · derivative · entry 1 Young Jeffrey E · CIK 0001367556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,364 Underlying: Common Stock, par value $0.01 per share · 10,364 shares Expires 2029-06-03 F1 · derivative.exercise_date: This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 3, 2019, December 3, 2019, March 3, 2020, and June 3, 2020. Read SEC document |
| November 13, 2018 Filed Nov 16, 2018 17:13 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantStock Option (right to buy) · Derivative | 10,897 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001144204-18-060553 · tv507511_form4.xml · derivative · entry 1 Young Jeffrey E · CIK 0001367556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,897 Underlying: Common Stock, par value $0.01 per share · 10,897 shares Expires 2028-11-13 F1 · derivative.exercise_date: The Stock Option shares will vest in four equal installments on February 13, 2019, May 13, 2019, August 13, 2019, and November 13, 2019. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 16:16 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | Disposition to issuerNonqualified Stock Option (right to buy) · Derivative | 170,000 | Not disclosed Strike: $5.60 | Not disclosed |
DisclosureSEC source: 0001209191-18-046773 · doc4.xml · derivative · entry 3 Young Jeffrey E · CIK 0001367556 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 170,000 shares Expires 2024-01-03 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 16:16 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 40,000 | Not disclosed Strike: $7.90 | Not disclosed |
DisclosureSEC source: 0001209191-18-046773 · doc4.xml · derivative · entry 2 Young Jeffrey E · CIK 0001367556 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2025-02-09 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 16:16 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | Disposition to issuerCommon Stock | 30,413 | $11.50 | $349,749.50 |
DisclosureSEC source: 0001209191-18-046773 · doc4.xml · nonDerivative · entry 1 Young Jeffrey E · CIK 0001367556 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the "Issuer") dated as of July 2, 2018. At the effective time of the merger (the "Effective Time") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the "Offer Price"). F2 · shares: Includes 27,150 restricted stock units that did not vest prior to the Effective Time of the merger. Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unvested 27,150 restricted stock units was cancelled in exchange for the Offer Price. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 16:13 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001209191-18-009524 · doc4.xml · derivative · entry 2 Young Jeffrey E · CIK 0001367556 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common stock, $0.01 par value per share · 40,000 shares Expires 2028-02-09 F2 · derivative.exercise_date: The option will be exercisable in 25% increments of the shares on each annual anniversary of the date of the grant. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 16:13 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | GrantCommon Stock | 18,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009524 · doc4.xml · nonDerivative · entry 1 Young Jeffrey E · CIK 0001367556 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,663 F1 · kind: This Restricted Stock Unit Award shall vest 25% on each anniversary of the date of grant over 4 years. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 19:45 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | Tax withholdingCommon Stock | 1,737 | $8.40 | $14,590.80 |
DisclosureSEC source: 0001209191-18-009018 · doc4.xml · nonDerivative · entry 2 Young Jeffrey E · CIK 0001367556 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,263 F2 · shares: The total number of shares acquired is net of the number of shares withheld for the payment of taxes. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 19:45 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009018 · doc4.xml · nonDerivative · entry 1 Young Jeffrey E · CIK 0001367556 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · kind: Represents shares of JNP common stock issued upon partial vesting of a restricted stock unit award that vests upon the compensation committee's certification of the achievement of certain performance/milestone goals. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 16:09 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | GrantNonqualified Stock Option (right to buy) · Derivative | 170,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-17-001981 · doc4.xml · derivative · entry 1 Young Jeffrey E · CIK 0001367556 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2024-01-03 F1 · security: This stock option is an inducement grant made pursuant to NASDAQ Stock Market Rule 5635(c). F2 · derivative.exercise_date: The option will be exercisable in 25% increments of the shares on each annual anniversary of the date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.